🔗 Share this article

While the US undertakes unprecedented changes to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines during the global health crisis and has zeroed in on potential fatalities following COVID-19 immunization in her recent time at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders planned to reveal major revisions to the pediatric vaccine schedule recently, aligning the US with the Danish national calendar, according to reports – a significant shift that would place the US out of step with many the international standard with no evidence for improved outcomes. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting some childhood immunization guidelines in the US in order to be more like Denmark's approach, a society with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Expertise

Høeg has no obvious track record in pharmaceutical research, oversight or leadership, which has been typical for previous heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the CDER, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in running a large organization. She lacks background in drug approvals.”

Past heads of CBER would “understand laws and regulations and the research of drug development”, commented Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who led the center have had.”

The drug center has an enormous range of responsibilities at the FDA, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars program, OTC medication office and so forth, and every single one have to be managed,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major administrative aspect to the job, which manages over 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” she added.

Response and Contentious Programs

When asked about concerns about Høeg’s credentials and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “concerns stem from inaccurate premises”.

“Her experience matches the duties of her role,” the official explained, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the agency head's controversial fast-track approval initiative, a disputed one-day medication authorization process that reportedly worried her former heads. “How are these medications being chosen for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed regulations of all drugs, with the exception of shots.”

Documented Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, track record, some experts have noted. She authored a analysis using non-validated public submissions to estimate the incidence of heart inflammation after Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are more dangerous than they are.

Among her “wish list” for the current government included altering rules for new vaccines and halting “non-essential” immunizations, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She’s an complete true believer who begins with her beliefs and works backwards to retrofit the science in a extremely misleading, untruthful way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|